Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Sima Maraqa

Internal Medicine Tulsa, OK Medical Doctor

NPI 1033696240 CMS profile 5347637

9228 S Mingo Rd, Tulsa, OK 74133

Open in the dashboard

General payments

$4,657

179 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sima Maraqa of Tulsa, OK is reported in the CMS Open Payments database as having received $4,657 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,526 55
2024 General $2,328 81
2023 General $684 38
2022 General $119 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sima Maraqa
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sima Maraqa were reported at $1,526. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sima Maraqa Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $119 $141 $42–$496 $149
2023 $684 $149 $45–$519 $160
2024 $2,328 $154 $47–$537 $164
2025 $1,526 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Abbott Laboratories $666 32 payments
  2. Dexcom, Inc. $603 39 payments
  3. Lilly USA, LLC $561 18 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $457 11 payments
  5. Novo Nordisk Inc $445 14 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $211 7 payments
  7. Insulet Corporation $156 1 payment
  8. Medtronic, Inc. $155 1 payment
  9. Tandem Diabetes Care, Inc. $155 8 payments
  10. Novartis Pharmaceuticals Corporation $140 7 payments
  11. Other $1,108 41 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,614 178 payments
  2. Education $43 1 payment
Products named General payments · program years 2022–2025
  1. FreeStyle Libre 3 $666 32 payments
  2. Dexcom G6 Transmitter $603 39 payments
  3. JARDIANCE Diabetes $417 9 payments
  4. JARDIANCE Diabetes $319 11 payments
  5. Ozempic $252 8 payments
  6. Kerendia $211 7 payments
  7. Wegovy $158 4 payments
  8. Omnipod $156 1 payment
  9. SIMPLERA SENSOR $155 1 payment
  10. t:slim X2 Insulin Pump with Control-IQ $155 8 payments
  11. Other $1,787 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,611

Median for Endocrinology: 1,959

Drug cost

$1,070,498

Median for Endocrinology: $890,201

Branded share of claims

66.5%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 208 $282,836
Ozempic Semaglutide Brand 204 $256,973
Jardiance Empagliflozin Brand 98 $123,880
Tresiba Flextouch U-200 Insulin Degludec Brand 35 $51,793
Farxiga Dapagliflozin Propanediol Brand 47 $48,062
Trulicity Dulaglutide Brand 25 $42,341
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 34 $41,821
Tresiba Flextouch U-100 Insulin Degludec Brand 53 $32,465
Prolia Denosumab Brand 15 $25,944
Genotropin Somatropin Brand 14 $24,128

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$124,939

Of which drugs: $44,449

Medicare patients

320

Average age 71

Services billed

3,146

229 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 58%
Arthritis 49%
Osteoporosis 36%
Ischemic heart disease 35%
Chronic kidney disease 31%
Depression 28%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 24 2,160 $44,449

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $263
  • Lilly USA, LLC $211
$474 98 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $180
$180 17 —
XARELTO
  • Janssen Pharmaceuticals, Inc $115
$115 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $111
$111 47 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record